Literature DB >> 8325046

Pharmacodynamic effects of single and repeated doses of oral sulodexide in healthy volunteers. A placebo-controlled study with an enteric-coated formulation.

M Mauro1, G C Palmieri, E Palazzini, M Barbanti, F Calanni Rindina, M R Milani.   

Abstract

Eight male and 8 female healthy volunteers, aged on average 32 +/- 6 years, underwent a randomized, crossover study, aimed at comparing the activity on some fibrinolysis and coagulation parameters of 100 and 200 mg/day of oral sulodexide, administered as enteric-coated tablets. After the single and the repeated (for 7 days) administration of the two daily dosages, the Fibrin Plates test, the Heptest, the Plasminogen Activator Inhibitor test (as to both activity and antigen level) and the activated Partial Thromboplastin Time were checked during the first 6 hours after administration. The pro-fibrinolytic and antithrombotic activity of sulodexide was confirmed to be significant with both dosage schemes and potentiated by repeated administrations. On the other hand, the absence of any influence on aPTT confirmed the lack of interference of the drug, after oral administration, on the intrinsic pathway of coagulation. No adverse reactions or events were observed.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8325046     DOI: 10.1185/03007999309111537

Source DB:  PubMed          Journal:  Curr Med Res Opin        ISSN: 0300-7995            Impact factor:   2.580


  6 in total

1.  Sulodexide promotes arterial relaxation via endothelium-dependent nitric oxide-mediated pathway.

Authors:  Joseph D Raffetto; Fiorella Calanni; Paolo Mattana; Raouf A Khalil
Journal:  Biochem Pharmacol       Date:  2019-04-20       Impact factor: 5.858

2.  Sulodexide Significantly Improves Endothelial Dysfunction and Alleviates Chest Pain and Palpitations in Patients With Long-COVID-19: Insights From TUN-EndCOV Study.

Authors:  Salma Charfeddine; Hassen Ibnhadjamor; Jihen Jdidi; Slim Torjmen; Salma Kraiem; Amine Bahloul; Ahmed Makni; Nesrine Kallel; Nedia Moussa; Mariem Boudaya; Imen Touil; Aiman Ghrab; Jamel Elghoul; Zeineb Meddeb; Yamina Thabet; Kais Ben Salem; Faouzi Addad; Kamel Bouslama; Sami Milouchi; Rania Hammami; Salem Abdessalem; Leila Abid
Journal:  Front Cardiovasc Med       Date:  2022-05-12

3.  Use of sulodexide in patients with peripheral vascular disease.

Authors:  J Lasierra-Cirujeda; P Coronel; Mj Aza; M Gimeno
Journal:  J Blood Med       Date:  2010-06-15

4.  Sulodexide Improves Contraction and Decreases Matrix Metalloproteinase-2 and -9 in Veins Under Prolonged Stretch.

Authors:  Joseph D Raffetto; Wentao Yu; Xi Wang; Fiorella Calanni; Paolo Mattana; Raouf A Khalil
Journal:  J Cardiovasc Pharmacol       Date:  2020-03       Impact factor: 3.271

5.  Sulodexide for Secondary Prevention of Recurrent Venous Thromboembolism: A Systematic Review and Meta-Analysis.

Authors:  Qing-Jun Jiang; Jun Bai; Jie Jin; Jian Shi; Lefeng Qu
Journal:  Front Pharmacol       Date:  2018-08-08       Impact factor: 5.810

Review 6.  Pharmacological Agents Targeting Thromboinflammation in COVID-19: Review and Implications for Future Research.

Authors:  Behnood Bikdeli; Mahesh V Madhavan; Aakriti Gupta; David Jimenez; John R Burton; Caroline Der Nigoghossian; Taylor Chuich; Shayan Nabavi Nouri; Isaac Dreyfus; Elissa Driggin; Sanjum Sethi; Kartik Sehgal; Saurav Chatterjee; Walter Ageno; Mohammad Madjid; Yutao Guo; Liang V Tang; Yu Hu; Laurent Bertoletti; Jay Giri; Mary Cushman; Isabelle Quéré; Evangelos P Dimakakos; C Michael Gibson; Giuseppe Lippi; Emmanuel J Favaloro; Jawed Fareed; Alfonso J Tafur; Dominic P Francese; Jaya Batra; Anna Falanga; Kevin J Clerkin; Nir Uriel; Ajay Kirtane; Claire McLintock; Beverley J Hunt; Alex C Spyropoulos; Geoffrey D Barnes; John W Eikelboom; Ido Weinberg; Sam Schulman; Marc Carrier; Gregory Piazza; Joshua A Beckman; Martin B Leon; Gregg W Stone; Stephan Rosenkranz; Samuel Z Goldhaber; Sahil A Parikh; Manuel Monreal; Harlan M Krumholz; Stavros V Konstantinides; Jeffrey I Weitz; Gregory Y H Lip
Journal:  Thromb Haemost       Date:  2020-05-30       Impact factor: 5.249

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.